Oxford PharmaGenesis was pleased to engage with other industry leaders at publication planning seminars in New Jersey and London last week. One topic that elicited much debate among the 100-plus in-house and agency pharmaceutical communications specialists was the wide-reaching, but so far unclear, implications of the US Sunshine Act. Opinion was divided about whether medical writing constituted transfer of value and delegates thought that further guidance was required from the US legislators. Real-world evidence was the other key topic for the day, with presenting journal editors Amitabh Prakash and Chris Carswell discussing its relevance to clinical practice and suitability for publication.